Rational drug design, synthesis and biological evaluation of dihydrofolate reductase inhibitors as antituberculosis agents

Papers of special note have been highlighted as: • of interest; •• of considerable interest.

References

• 1 Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282(7), 677–686 (1999).
  Medline CASGoogle Scholar
• 2 Globaltuberculosisreport http://apps.who.int.
  Google Scholar
• 3 Zignol M, Hosseini MS, Wright A et al. Global incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 194(4), 479–485 (2006).
  MedlineGoogle Scholar
• 4 Schnell JR, Dyson HJ, Wright PE. Structure, dynamics, and catalytic function of dihydrofolate reductase. Ann. Rev. Biophys. Biomol. Strut. 33, 119–140 (2004).
  Medline CASGoogle Scholar
• 5 Berman EM, Werbel LM. The renewed potential for folate antagonists in contemporary cancer chemotherapy. J. Med. Chem. 34(2), 479–485 (1991).
  Medline CASGoogle Scholar
• 6 Gerum AB, Ulmer JE, Jacobus DP, Jensen NP, Sherman DR, Sibley CH. Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacteriumtuberculosis dihydrofolate reductase. Antimicrob. Agents Chemother. 46(11), 3362–3369 (2002).
  Medline CASGoogle Scholar
• 7 Li R, Sirawaraporn R, Chitnumsub P et al. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J. Mol. Biol. 295(2), 307–323 (2000).•• Provides the crystal structure of the Mtb DHFR enzyme, which provides a basis for the rational drug design.
  Medline CASGoogle Scholar
• 8 El-Hamamsy MH, Smith AW, Thompson AS, Threadgill MD. Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis. Bioorg. Med. Chem. 15(13), 4552–4576 (2007).
  Medline CASGoogle Scholar
• 9 Reynolds RC, Campbell SR, Fairchild RG et al. Novel boron-containing, nonclassical antifolates: Synthesis and preliminary biological and structural evaluation. J. Med. Chem. 50(14), 3283–3289 (2007).
  Medline CASGoogle Scholar
• 10 Kumar A, Siddiqi MI. Virtual screening against Mycobacterium tuberculosis dihydrofolate reductase: Suggested workflow for compound prioritization using structure interaction fingerprints. J. Mol. Graph. 27(4), 476–488 (2008).
  CASGoogle Scholar
• 11 Kumar M, Vijayakrishnan R, Subba Rao G. In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery. Mol. Divers. 14(3), 595–604 (2010).
  Medline CASGoogle Scholar
• 12 Bag S, Tawari NR, Degani MS. Insight into inhibitory activity of mycobacterial dihydrofolate reductase inhibitors by in silico molecular modeling approaches. QSAR Comb. Sci. 28(3), 296–311 (2009).•• Provides the direction for carrying out the in silico analysis for this manuscript.
  CASGoogle Scholar
• 13 Tawari NR, Bag S, Degani MS. A review of molecular modelling studies of dihydrofolate reductase inhibitors against opportunistic microorganisms and comprehensive evaluation of new models. Curr. Pharm. Des. 17(7), 712–751 (2011).
  Medline CASGoogle Scholar
• 14 Bag S, Tawari NR, Queener SF, Degani MS. Synthesis and biological evaluation of biguanide and dihydrotriazine derivatives as potential inhibitors of dihydrofolate reductase of opportunistic microorganisms. J. Enzyme Inhib. Med. Chem. 25(3), 331–339 (2010).
  Medline CASGoogle Scholar
• 15 Degani MS, Bag S, Bairwa R, Tawari NR, Queener SF. Novel 2-hydrazino-pyrimidin-4(3H)-one derivatives as potential dihydrofolate reductase inhibitors. J. Heterocycl. Chem. 47(3), 558–563 (2010).
  CASGoogle Scholar
• 16 Bag S, Tawari NR, Degani MS, Queener SF. Design, synthesis, biological evaluation and computational investigation of novel inhibitors of dihydrofolate reductase of opportunistic pathogens. Bioorg. Med. Chem. 18(9), 3187–3197 (2010).• The reference aided in holistic approach for targeting DHFR of Mycobacterium tuberculosis.
  Medline CASGoogle Scholar
• 17 Raju A, Khedkar MA, Degani MS. Optimization of Mycobacterium tuberculosis DHFR production from recombinant Saccharomyces cerevisiae. Int. J. Curr. Microb. App. Sci. 2(6), 70–79 (2013).
  Google Scholar
• 18 Raju A, Degani MS, Khedkar MA, Niphadkar SA. Novel affinity chromatographic technique for purification of dihydrofolate reductase from recombinant yeast. Int. J. Drug Des. Discov. 4(1), 994–997 (2013).• This publication was referred for the enzyme isolation and purification protocols.
  CASGoogle Scholar
• 19 Maestro, version 8.0 Schrödinger, LLC, NY, USA (2007).
  Google Scholar
• 20 LigPrep, version 3.0, Schrödinger, LLC, NY, USA (2008)., User manual.
  Google Scholar
• 21 Glide, Version 5.0, Schrödinger, LLC, NY, USA (2008), User manual.
  Google Scholar
• 22 ZINC database. http://zinc.docking.org.
  Google Scholar
• 23 Bairwa R, Kakwani M, Tawari NR et al. Novel molecular hybrids of cinnamic acids and guanylhydrazones as potential antitubercular agents. Bioorg. Med. Chem. Lett. 20(5), 1623–1625 (2010).
  Medline CASGoogle Scholar
• 24 Palomino JC, Martin A, Camacho M, Guerra H, Swings J, Portaels F. Resazurin microtiter assay plate: Simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46(8), 2720–2722 (2002).•• Gives the technique for the biological in vitro whole cell assay.
  Medline CASGoogle Scholar
• 25 Freshney R L. J. Heterocyclic Chemistry Culture of Animal Cells: A Manual of Basic Techniques (4th Edition). Willy-LISS, (2000).
  Google Scholar
• 26 Khan A, Sarkar S, Sarkar D. Bactericidal activity of 2-nitroimidazole against the active replicating stage of Mycobacterium bovis BCG and Mycobacterium tuberculosis with intracellular efficacy in THP-1 macrophages. Int. J. Antimicrob. Agents. 32, 40–45 (2008).
  Medline CASGoogle Scholar
• 27 Singh U, Akhtar S, Mishr A, Sarkar D. A novel screening method based on menadione mediated rapid reduction of tetrazolium salt for testing of anti-mycobacterial agents. J. Microbiol. Methods 84, 202–207 (2011).• This reference gives the protocol for in vitro testing against dormant tubercle bacilli.
  Medline CASGoogle Scholar
• 28 Sarkar S, Sarkar D. Potential use of nitrate reductase as a biomarker for the identification of active and dormant inhibitors of Mycobacterium tuberculosis in a THP1 Infection Model. J. Biomol. Screen. 17(7), 966–973 (2012).• Gives the protocol for ex vivo testing in infectious model.
  MedlineGoogle Scholar
• 29 White EL, Ross LJ, Cunningham A, Escuyer V. Cloning, expression, and characterization of Mycobacterium tuberculosis dihydrofolate Reductase. FEMS Microbiol. Lett. 232, 101–105 (2004).•• Discusses the DHFR enzyme assay protocol.
  Medline CASGoogle Scholar
• 30 Hillcoat BL, Nixon PF, Blakley RL. Effect of substrate decomposition on the spectrophotometric assay of dihydrofolate reductase. Anal. Biochem. 21, 178–189 (1967).
  Medline CASGoogle Scholar
• 31 Topliss JG. A manual method for applying the Hansch approach to drug design. J. Med. Chem. 20(4), 463–469 (1977).
  Medline CASGoogle Scholar